GargABirabaharanMStrunkA.Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2018;79(1):71-76. doi:10.1016/j.jaad.2018.03.036
2.
Rodriguez-ZunigaMJGarcia-PerdomoHAOrtega-LoayzaAG.Association between hidradenitis suppurativa and metabolic syndrome: a systematic review and meta-analysis. Actas Dermosifiliogr (Engl Ed). 2019;110(4):279-288. doi:10.1016/j.adengl.2019.03.017
3.
GargAMalviyaNStrunkA, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092-1101. doi:10.1016/j.jaad.2021.01.059
4.
Sánchez-FelicianoAHerreraHCharrowABarbieriJS.Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: a systematic review. J Am Acad Dermatol. 2025;93(5):1334-1337. doi:10.1016/j.jaad.2025.06.077
5.
NielsenVWVadOBHolgersenN, et al. Genetic susceptibility to hidradenitis suppurativa and predisposition to cardiometabolic disease. JAMA Dermatol. 2025;161(1):22-30. doi:10.1001/jamadermatol.2024.3779
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
